DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 199 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $828,377 | -39.6% | 40,154 | -13.6% | 0.05% | -37.8% |
| Q2 2023 | $1,371,477 | +21.9% | 46,475 | -4.8% | 0.07% | +5.7% |
| Q1 2023 | $1,124,974 | +172.1% | 48,827 | +228.4% | 0.07% | +159.3% |
| Q4 2022 | $413,451 | +3.9% | 14,867 | +14.7% | 0.03% | -6.9% |
| Q3 2022 | $398,000 | +5.9% | 12,962 | +1.5% | 0.03% | +20.8% |
| Q2 2022 | $376,000 | -18.1% | 12,776 | -10.4% | 0.02% | +26.3% |
| Q1 2022 | $459,000 | -35.0% | 14,254 | -10.0% | 0.02% | -17.4% |
| Q4 2021 | $706,000 | -20.8% | 15,840 | -10.3% | 0.02% | -23.3% |
| Q3 2021 | $891,000 | +324.3% | 17,653 | +560.9% | 0.03% | +328.6% |
| Q2 2021 | $210,000 | – | 2,671 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
| Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
| Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
| Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
| MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
| Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
| PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
| HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |